Enterococcus causes 14% of all hospital-associated infections (HAIs) according to Centers for Disease Control and Prevention (CDC) data. 35.5% of these HAIs are caused by Vancomycin-resistant Enterococci (VRE) including highly fatal bacteremia, surgical site infections, and urinary tract infections. We present a novel synthetic compound, HSD 03-21 that could make VRE completely susceptible to vancomycin in-vitro.
Reduction in Endotracheal Aspirate Cultures after Implementation of a Diagnostic Stewardship Intervention in a Pediatric Intensive Care Unit
Anna Sick-Samuels, MD, MPH 1 ; Jules Bergmann, MD 1 ; Matthew Linz, BS 1 ; James Fackler, MD 1 ; Sean Berenholtz, MD 1 ; Joe Dwyer, MAEd, EdD(c), RRT 2 ; Katherine Hoops, MD, MPH 1 ; Elizabeth Colantuoni, PhD 3 and Aaron Milstone, MD, MHS 1 ; 1 Johns Hopkins University School of Medicine, Baltimore, Maryland; 2 Johns Hopkins Hospital, Baltimore, Maryland; 3 Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland Session: 228. Pediatric Stewardship Saturday, October 5, 2019: 10:30 AM Background. Clinicians obtain endotracheal aspirate (ETA) cultures from mechanically ventilated patients in the pediatric intensive care unit (PICU) for the evaluation of ventilator-associated infection (i.e., tracheitis or pneumonia). Positive cultures prompt clinicians to treat with antibiotics even though ETA cultures cannot distinguish bacterial colonization from infection. We undertook a quality improvement initiative to standardize the use of endotracheal cultures in the evaluation of ventilator-associated infections among hospitalized children.
Methods. A multidisciplinary team developed a clinical decision support algorithm to guide when to obtain ETA cultures from patients admitted to the PICU and ventilated for >1 day. We disseminated the algorithm to all bedside providers in the PICU in April 2018 and compared the rate of cultures one year before and after the intervention using Poisson regression and a quasi-experimental interrupted time-series models. Charge savings were estimated based on $220 average charge for one ETA culture.
Results. In the pre-intervention period, there was an average of 46 ETA cultures per month, a total of 557 cultures over 5,092 ventilator-days; after introduction of the algorithm, there were 19 cultures obtained per month, a total of 231 cultures over 3,554 ventilator-days (incident rate 10.9 vs. 6.5 per 100 ventilator-days, Figure 1 ). There was a 43% decrease in the monthly rate of cultures (IRR 0.57, 95% CI 0.50-0.67, P < 0.001). The ITSA revealed a pre-existing 2% decline in the monthly culture rate (IRR 0.98, 95% CI 0.97-1.00, P = 0.01), an immediate 44% drop (IRR 0.56, 95% CI 0.45-0.69, P = 0.02) and a stable rate in the post-intervention period (IRR 1.03, 95% CI 0.99-1.07, P = 0.09). The intervention led to an estimated $6000 in monthly charge savings.
Conclusion. Introduction of a clinical decision support algorithm to standardize the obtainment of ETA cultures from ventilated children was associated with a significant decline in the rate of ETA cultures. Additional investigation will assess the impact on balancing measures and secondary outcomes including mortality, duration of ventilation, duration of admission, readmissions, and antibiotic prescribing.
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Impact of β-Lactam Antibiotic Allergy on Antimicrobial Use, Clinical Outcomes, and Costs for Hospitalized Children
Trahern Wallace Jones, MD 1 ; Nora Fino, MS 1 ; Jared Olson, PharmD 1 ; Lauri Hicks, DO 2 ; Katherine E. Fleming-Dutra, MD 2 and Adam Hersh, MD, PhD 3 ; 1 University of Utah School of Medicine, Salt Lake City, Utah; 2 Centers for Disease Control and Prevention, Atlanta, Georgia; 3 University of Utah, Salt Lake City, Utah Session: 228. Pediatric Stewardship Saturday, October 5, 2019: 10:45 AM Background. Most β-lactam antibiotic allergies (BLA) are incorrectly diagnosed and could be de-labeled. Adult patients with BLA are more likely to receive broader-spectrum antimicrobials and experience worse health outcomes than nonallergic patients. Similar studies on the impact of BLA on antimicrobial use and clinical outcomes are limited in pediatrics. Our objective was to compare antimicrobial use, and clinical and economic outcomes between hospitalized children with and without BLA.
Methods. This was a retrospective cohort of pediatric patients hospitalized at an Intermountain Healthcare (IH) hospital from 2007 to 2017. IH has 22 hospitals including one children's hospital. Patients aged 30 days-17 years who received ≥1 dose of an antimicrobial during hospitalization were included. The exposure variable was the presence of BLA (penicillins or cephalosporins) in the allergy field of the medical record. Patients with BLA were matched to nonallergic controls on age, sex, race, clinical service line, admission date, children's hospital or other hospital, and co-morbid conditions. We used multivariable log-transformed-linear and logistic regression models to compare patients with BLA to controls in terms of antibiotic selection and total antimicrobial days, antimicrobial cost, length-of-stay (LOS) and 30-day readmission. For antibiotic selection we examined the odds of receiving the following broader-spectrum agents individually and in composite: vancomycin, fluoroquinolones, clindamycin, carbapenems, and macrolides.
